Article 5.02 Departure of directors or certain officers; Election of directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
On July 18, 2022, InMed Pharmaceuticals Inc. (the “Company”) has issued a press release announcing that it has appointed Mr. Michael Woudenberg as Chief Operating Officer of the Company from July 15, 2022 (the “Effective Date”). He was previously Senior Vice President of Chemistry, Manufacturing and Controls. Mr. Woudenberg has been an integral part of the management team for four years, supporting multiple functions within the company. Before joining the Company, Mr. Woudenberg had over 20 years of successful experience in drug development, process engineering, GMP manufacturing and general management at all levels of various companies, including, most recently, as Managing Director of Phyton Biotech of March 2016 at October 2018.
As part of his appointment, Mr. Woudenberg and the Company has entered into an employment contract dated July 15, 2022 (the “Employment Agreement”), under which he will receive an annual base salary of C$300,000. He is also eligible for an annual discretionary bonus, targeted at 40% of his base salary, which will be subject to approval by the Corporation’s Board and Compensation Committee. The employment contract contains certain covenants that apply during and after his employment, including confidentiality, non-competition and non-solicitation agreements.
There is no family relationship between Mr. Woudenberg and the Company. There are no related party transactions with Mr. Woudenberg must be disclosed pursuant to Regulation SK Section 404(a).
Section 7.01 Disclosure of FD Rules.
On July 18, 2022the Company issued a press release announcing the appointment of Mr. Woudenberg. A copy of the press release is provided as Exhibit 99.1 hereto and is incorporated herein by reference.
The information set forth in this Section 7.01, including Exhibit 99.1, is provided and will not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). ), or otherwise subject to the liabilities of this section. The information set forth in this Section 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference in any other filing under the Securities Act 1933, as amended, or the Exchange Act, unless expressly stated by specific reference in such filing.
Item 9.01. Financial statements and supporting documents.
The following document will be deemed provided and not filed:
Exhibit No. Description
10.1 Employment Agreement dated July 15, 2022, between InMed
Pharmaceuticals Inc. and Michael Woudenberg
99.1 Press Release, dated July 18, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document and included as Exhibit 101)
© Edgar Online, source Previews